When did Kymera Therapeutics report Q4 2024 earnings?

Kymera Therapeutics (KYMR) reported Q4 2024 earnings on February 27, 2025 before market open.

What were Kymera Therapeutics's Q4 2024 revenue and EPS?

Kymera Therapeutics reported revenue of $7.4M and eps of $-0.88 for Q4 2024.

Did Kymera Therapeutics beat estimates in Q4 2024?

Revenue missed the consensus estimate of $16.7M by $9.3M. EPS missed the consensus estimate of $-0.76 by $0.12.

Where can I find Kymera Therapeutics's Q4 2024 SEC filings?

You can read the 10-K periodic report (0000950170-25-028355) directly on SEC EDGAR. The filing index links above go to sec.gov.

Kymera Therapeutics KYMR Q4 2024 Annual earnings

Reported February 27, 2025 · Before market open

Revenue$7.4MMiss by $9.3M

EPS-$0.88Miss by $0.12

Revenue estimate$16.7M

EPS estimate-$0.76

Next report

Aug 10, 2026 (In 1 week)

Revenue estimate$32.2M

EPS estimate-$0.72

Financials

Q4 2024

Income statement

See full

Revenue$7.4M-84.6%

Operating income-$80.8M-318%

Net income-$70.8M-392%

EPS (diluted)-$0.89-256%

Balance sheet

See full

Cash & equivalents$120.3M+9.4%

Total debt$89.3M+3.9%

Total equity$835.6M+112%

Total assets$978.0M+69.9%

Cash flow

See full

Operating cash flow-$61.8M—

CapEx$936.0K-91.9%

Free cash flow-$62.7M-1,652%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$2.61B+74.9%

Enterprise value$2.57B+75.6%

P/S55.4×+36.4×

Profitability

See full

Operating margin-555.8%-1,426pp

Net margin-475.6%-1,351pp

FCF margin-440.5%-1,286pp

Returns & leverage

See full

Return on equity-36.4%+3.8pp

Debt / equity0.1×-0.1×

Current ratio7.5×+2.8×

Versus estimates

Revenue

Q1 2026$34.4MBeat by $26.1M Q4 2025$2.9MMiss by $12.2M Q3 2025$2.8MMiss by $11.7M Q2 2025$11.5MMiss by $5.7M Q1 2025$22.1MBeat by $9.7M

Q4 2024$7.4MMiss by $9.3M

Diluted EPS

Q1 2026-$0.71Beat by $0.18 Q4 2025-$0.97Miss by $0.19 Q3 2025-$0.90Miss by $0.19 Q2 2025-$0.95Miss by $0.12 Q1 2025-$0.82Beat by $0.10

Q4 2024-$0.88Miss by $0.12

Ask the moment Kymera Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Kymera Therapeutics report Q4 2024 earnings?: Kymera Therapeutics (KYMR) reported Q4 2024 earnings on February 27, 2025 before market open.
What were Kymera Therapeutics's Q4 2024 revenue and EPS?: Kymera Therapeutics reported revenue of $7.4M and eps of $-0.88 for Q4 2024.
Did Kymera Therapeutics beat estimates in Q4 2024?: Revenue missed the consensus estimate of $16.7M by $9.3M. EPS missed the consensus estimate of $-0.76 by $0.12.
Where can I find Kymera Therapeutics's Q4 2024 SEC filings?: You can read the 10-K periodic report (0000950170-25-028355) directly on SEC EDGAR. The filing index links above go to sec.gov.